Mirum Pharmaceuticals, Inc. announced an Agreement and Plan of Merger and Reorganization on December 6, 2025, to merge with Bluejay Therapeutics for $250 million in cash and approximately $370 million in stock, plus potential milestone payments of up to $200 million based on sales. The expected closing of the merger is in Q1 2026, subject to regulatory approvals.